陶氏健骨汤治疗原发性骨质疏松症的临床效果
| 作者: |
1郁啸云,
2刘淑玮,
1盛韶山
1 温岭市中医院骨伤科，浙江 温岭 317500 2 温岭市中医院内科，浙江 温岭 317500 |
| 通讯: |
郁啸云
Email: 119454233@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2017.01.007 |
| 基金: | 温岭市科技局科研项目, 2013C31BC0002 |
摘要
目的：观察评价陶氏健骨汤治疗骨质疏松症的临床效果。方法：将120例骨质疏松症患者随机分为治疗组和对照组，治疗组服用陶氏健骨汤，对照组服用钙尔奇D片，观察各组在治疗前、治疗3个疗程(4周为1个疗程)后的临床体征、骨代谢生化指标、性激素、骨形成生化指标、骨吸收生化指标的变化。结果：治疗后两组患者中医症状均减轻，差异有统计学意义(P<0.05)；治疗后组间比较，治疗组腰背疼痛、腰膝酸软、抽筋、步履艰难等症状程度轻于对照组，差异有统计学意义(P<0.05)。治疗结束后，两组甲状旁腺激素(parathyroid hormone，PTH)、血钙(S-Ca)均较治疗前降低，降钙素(calcitonin，CT)较治疗前升高，差异有统计学意义(P<0.05)；治疗组患者治疗后性激素(E2、T)含量升高，差异有统计学意义(P<0.05)；对照组患者治疗前后性激素(E2，T)变化差异无统计学意义(P>0.05)。两组患者治疗后碱性磷酸酶(alkaline phosphatase，ALP)、骨钙素(bone glaprotein，BGP)均较治疗前上升(P<0.05)；且治疗后组间比较，治疗组ALP，BGP均高于对照组，差异有统计学意义(P<0.05)。两组患者治疗后U-HYP/Cr，U-Ca/Cr，TRAP均明显下降，差异有统计学意义(P<0.05)；治疗后，治疗组U-HYP/Cr，U-Ca/Cr，TRAP均低于对照组，差异有统计学意义(P<0.05)。结论：陶氏健骨汤具有提高雌激素水平，抑制骨吸收，促进骨形成等功能，是治疗骨质疏松的有效方药。
关键词：
陶氏健骨汤
骨质疏松症
临床研究
Clinical efficacy of Taoshi jiangu decoction in the treatment of primary osteoporosis
CorrespondingAuthor: YU Xiaoyun Email: 119454233@qq.com
DOI: 10.3978/j.issn.2095-6959.2017.01.007
Abstract
Objective: To observe the clinical efficacy of Taoshi jiangu decoction on osteoporosis. Methods: One hundred and twenty patients with osteoporosis were randomly divided into treatment and control groups. Patients were treated by Taoshi jiangu decoction in a treatment group and Caltrate D in a control group. The E2, T, HYP, bone glaprotein (BGP), alkaline phosphatase (ALP), U-Ca, TRAP, parathyroid hormone (PTH), CT, S-Ca and S-P were tested. Results: The TCM clinical symptoms were relieved in the two groups. And there was statistical difference on pain of the back, soreness and weakness of the lumbar region and difficulty of walking. After the treatment, PTH and S-Ca reduced and the calcitonin (CT) increased in two groups, with statistical difference (P<0.05). The E2 and T increased in treatment group (P<0.05), while the change in control group showed no statistical difference (P>0.05); ALP and BGP increased in two groups, with statistical difference (P<0.05); and ALP and BGP showed higher in the treatment group than those in the control group, with statistical difference (P<0.05). The U-HYP/Cr, U-Ca/Cr and TRAP reduced in two groups (P<0.05), and U-HYP/Cr, U-Ca/Cr and TRAP showed lower in the treatment group than those in the control group, with statistical difference (P<0.05). Conclusion: Taoshi jiangu decoction can increase estrogen levels, inhibit bone resorption and promote bone formation in patients with osteoporosis. It is effective for osteoporosis.